LeonaBio Inc (LONA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$4.84-2.62%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge LeonaBio Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.603
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-2.835
Annual ending 2027-12-31
Revenue	—	0
EPS	—	-2.34

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Complete acquisition and integration of Sermonix	A primary condition in LeonaBio Inc's published investment case. The stated target is Acquisition completed and integrated by end of 2026.	Intact	Acquisition not completed or integration fails by FY26	Acquisition terms filed (Mar 2026); no completion date reported March 2026 filing details Sermonix License and Securities Issuance terms. No news of integration failure or missed deadlines. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Advance development of lasofoxifene drug	The company is developing lasofoxifene to strengthen its drug pipeline.	Intact	No meaningful progress in lasofoxifene development by FY26	Phase 3 ELAINE-3 trial advanced with 500th subject enrolled News reports Phase 3 ELAINE-3 trial advancement and 500th subject enrollment, confirming lasofoxifene development progress. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Improve cash flow from operations	It aims to improve cash flow from operations, now negative $20.9M in Q1 2026.	Broken	Negative cash flow worsens or stays near -$20.9M in FY26	Cash from operations: $-16.958M FY2026-Q2; GAAP. Published target: Reduce negative cash flow from operations by 50% by end 2026. Target and observation units differ. Source published Aug 14, 2026-16,958,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	3 / 3
2026-07-25	Unavailable	Unavailable	2 / 0
2026-07-26	Unavailable	Unavailable	3 / 3
2026-07-27	Unavailable	Unavailable	3 / 3
2026-07-28	Unavailable	Unavailable	3 / 3
2026-07-29	Unavailable	Unavailable	2 / 0
2026-07-30	Unavailable	Unavailable	3 / 3
2026-07-31	Unavailable	Unavailable	3 / 3
2026-08-01	Unavailable	Unavailable	2 / 0
2026-08-02	Unavailable	Unavailable	3 / 3
2026-08-03	Unavailable	Unavailable	2 / 0
2026-08-04	Unavailable	Unavailable	3 / 3
2026-08-05	Unavailable	Unavailable	2 / 0
2026-08-06	Unavailable	Unavailable	3 / 3
2026-08-07	Unavailable	Unavailable	2 / 0
2026-08-08	Unavailable	Unavailable	3 / 3
2026-08-09	Unavailable	Unavailable	3 / 3
2026-08-10	Unavailable	Unavailable	3 / 3
2026-08-12	Unavailable	Unavailable	2 / 0
2026-08-13	Unavailable	Unavailable	3 / 3
2026-08-14	Unavailable	Unavailable	2 / 0
2026-08-15	Unavailable	Unavailable	2 / 0
2026-08-16	Unavailable	Unavailable	2 / 0
2026-08-17	Unavailable	Unavailable	2 / 0
2026-08-18	Unavailable	Unavailable	2 / 0
2026-08-19	Unavailable	Unavailable	2 / 0
2026-08-20	Unavailable	Unavailable	2 / 0
2026-08-21	Unavailable	Unavailable	3 / 0
2026-08-22	Unavailable	Unavailable	3 / 0
2026-08-23	Unavailable	Unavailable	3 / 0
2026-08-24	Unavailable	Unavailable	3 / 0
2026-08-25	Unavailable	Unavailable	3 / 0
2026-08-26	Unavailable	Unavailable	3 / 0
2026-08-27	Unavailable	Unavailable	3 / 0
2026-08-28	Unavailable	Unavailable	3 / 0
2026-08-29	Unavailable	Unavailable	3 / 0
2026-08-30	Unavailable	Unavailable	3 / 0
2026-08-31	Unavailable	Unavailable	3 / 0
2026-09-01	Unavailable	Unavailable	3 / 0
2026-09-02	Unavailable	Unavailable	3 / 0
2026-09-03	Unavailable	Unavailable	3 / 0
2026-09-04	Unavailable	Unavailable	3 / 0
2026-09-05	Unavailable	Unavailable	3 / 0
2026-09-06	Unavailable	Unavailable	3 / 0
2026-09-07	Unavailable	Unavailable	3 / 0
2026-09-08	Unavailable	Unavailable	3 / 0
2026-09-09	Unavailable	Unavailable	3 / 0
2026-09-10	Unavailable	Unavailable	3 / 0
2026-09-11	Unavailable	Unavailable	3 / 0
2026-09-12	Unavailable	Unavailable	3 / 0
2026-09-13	Unavailable	Unavailable	3 / 0
2026-09-14	Unavailable	Unavailable	3 / 0
2026-09-15	Unavailable	Unavailable	3 / 0
2026-09-16	Unavailable	Unavailable	3 / 0
2026-09-17	Unavailable	Unavailable	3 / 0
2026-09-18	Unavailable	Unavailable	3 / 0
2026-09-19	Unavailable	Unavailable	3 / 0
2026-09-20	Unavailable	Unavailable	3 / 0
2026-09-21	Unavailable	Unavailable	3 / 0
2026-09-22	Unavailable	Unavailable	3 / 0
2026-09-23	Unavailable	Unavailable	3 / 0
2026-09-24	Unavailable	Unavailable	3 / 0
2026-09-25	Unavailable	Unavailable	3 / 0
2026-09-26	Unavailable	Unavailable	3 / 0
2026-09-27	Unavailable	Unavailable	3 / 0
2026-09-28	Unavailable	Unavailable	3 / 0
2026-09-29	Unavailable	Unavailable	3 / 0
2026-09-30	Unavailable	Unavailable	3 / 0
2026-10-01	Unavailable	Unavailable	3 / 0
2026-10-02	Unavailable	Unavailable	3 / 0
2026-10-03	Unavailable	Unavailable	3 / 0
2026-10-04	Unavailable	Unavailable	3 / 0
2026-10-05	Unavailable	Unavailable	3 / 0
2026-10-06	Unavailable	Unavailable	3 / 0
2026-10-07	Unavailable	Unavailable	3 / 0
2026-10-08	Unavailable	Unavailable	3 / 0
2026-10-09	Unavailable	Unavailable	3 / 0
2026-10-10	Unavailable	Unavailable	3 / 0
2026-10-11	Unavailable	Unavailable	3 / 0
2026-10-12	Unavailable	Unavailable	3 / 0
2026-10-13	Unavailable	Unavailable	3 / 0
2026-10-14	Unavailable	Unavailable	3 / 0
2026-10-15	Unavailable	Unavailable	3 / 0
2026-10-16	Unavailable	Unavailable	3 / 0
2026-10-17	Unavailable	Unavailable	3 / 0
2026-10-18	Unavailable	Unavailable	3 / 0
2026-10-19	Unavailable	Unavailable	3 / 0
2026-10-20	Unavailable	Unavailable	3 / 0
2026-10-21	Unavailable	Unavailable	3 / 0
2026-10-22	Unavailable	Unavailable	3 / 0
2026-10-23	Unavailable	Unavailable	3 / 0
2026-10-24	Unavailable	Unavailable	3 / 0

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	3	1
2026-06-01	3	1
2026-07-01	4	0
2026-08-01	4	0
2026-09-01	4	0
2026-10-01	4	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 4 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Improve cash flow from operationsPublished status: Broken

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

1 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.9%Typical daily move · historical

Downside history

-75.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

LeonaBio Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage growth, not an established earnings compounder. The thesis is intact, with management on track against two trial milestones, but confidence is low and the business remains loss-making.

What's priced into LeonaBio Inc

The snapshot provides no valuation or explicit market-expectations evidence, so whether LONA is cheap or expensive versus peers cannot be assessed. Recent financial performance is described as holding in the top half of its industry, while the stock’s recent price reaction was down; the evidence does not explain what expectations that reaction reflects.

What the fundamentals likely do

Near term, earnings remain uncertain: LONA had an August earnings beat, but its recent surprises are erratic and the next-quarter miss risk is elevated. Over the multi-year view, enrollment in the Phase 3 ELAINE-3 trial is on track for completion by Q4 2026, with topline data expected in the second half of 2027; management also plans to start a Phase 2 ATH-1105 trial in the second half of 2026. Cash and investments declined from Q1 to Q2 2026, so funding remains a key constraint despite prior financing.

What LeonaBio Inc hinges on

The thesis depends on completing enrollment and reaching the stated data timeline for ELAINE-3, while advancing ATH-1105 into its planned Phase 2 trial. It also hinges on whether available resources can support those milestones as cash declines. Near term, weakening jobs data could weigh on cyclical names, while continued strength or weakness among healthcare bellwethers could reinforce or fade the sector tailwind.